Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Prospective Evaluation of Rifalazil Effect On Vascular Symptoms of Intermittent Claudication and Other Endpoints in Chlamydia Seropositive Patients

NCT00251849 is registered in ClinicalTrials.gov with ActivBiotics as lead sponsor.

NCT NCT00251849
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00251849 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Prospective Evaluation of Rifalazil Effect On Vascular Symptoms of Intermittent Claudication and Other Endpoints in Chlamydia Seropositive Patients
Lead sponsor
ActivBiotics
Phase
Phase 3
Overall status
Unknown status
Start date
November 30, 2005
Completion date
December 31, 2007
Enrollment
274
Sites
48

Conditions

As the registry lists them; a condition with its own page is linked.

intermittent claudication, peripheral vascular diseases